Jefferies Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Jefferies Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$401K	Sell	3,046 -42,930	-93%	-$5.7M	﹤0.01%	1299
2025 Q4	$6.52M	Buy	+45,976	New	+$6.66M	0.03%	431
2025 Q2	–	Sell	-4,500	Closed	-$498K	–	1650
2025 Q1	$498K	Buy	+4,500	New	+$570K	﹤0.01%	1046
2024 Q4	–	Sell	-4,390	Closed	-$506K	–	1743
2024 Q3	$506K	Sell	4,390 -390	-8%	-$53.5K	﹤0.01%	975
2024 Q2	$658K	Sell	4,780 -1,155	-19%	-$158K	0.01%	878
2024 Q1	$819K	Sell	5,935 -691	-10%	-$94.4K	0.01%	894
2023 Q4	$873K	Buy	+6,626	New	+$763K	0.01%	1011
2023 Q1	–	Sell	-14,511	Closed	-$1.73M	–	1865
2022 Q4	$1.73M	Buy	+14,511	New	+$1.7M	0.01%	704

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's NBIX Position: Q1 2026 in Review

Jefferies Financial Group reduced its Neurocrine Biosciences (NBIX) stake by 93% in Q1 2026, selling an estimated $5.7M and leaving 3,046 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Jefferies Financial Group first reported a position in NBIX in Q4 2022 and has held it in 8 quarters since. The position peaked at $6.52M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Jefferies Financial Group held 3,046 shares of Neurocrine Biosciences worth $401K as of Q1 2026.
Jefferies Financial Group sold 42,930 Neurocrine Biosciences shares in Q1 2026, an estimated $5.7M.
Neurocrine Biosciences made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1299 holding.
Jefferies Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 8 quarters since.
Jefferies Financial Group's Neurocrine Biosciences position peaked at $6.52M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.